The decision from the Ministry of Health, Labour, and Welfare was supported by phase 3 LUNAR trial results showing an OS benefit with Optune Lua in NSCLC.

Experts detailed key advances in myelofibrosis, multiple myeloma, and lymphoma at the Society of Hematologic Oncology 2025 Annual Meeting.

Ateganosine plus cemiplimab was well tolerated in patients with heavily pretreated advanced NSCLC, with most adverse effects grades 1/2 in severity.

A group of community and academic oncologists exchanged ideas on optimizing therapy across different prostate, kidney, and bladder cancer populations.

All efficacy-evaluable patients with ES-SCLC treated with surufatinib, durvalumab, etoposide, and chemotherapy responded to treatment.

Lorenzo Falchi, MD, highlighted the most important considerations when using novel immunotherapy combination therapies for patients with indolent lymphoma.